Law.com Subscribers SAVE 30%

Call 855-808-4530 or email [email protected] to receive your discount on a new subscription.

More Same-Sex News from Massachusetts Image

More Same-Sex News from Massachusetts

ALM Staff & Law Journal Newsletters

Massachusetts' Supreme Judicial Court agreed on Jan. 29 to hear an appeal to a case that last summer upheld application of a state law that prevents out-of-state same-sex couples from marrying in Massachusetts. The underlying suit, <i>Cote-Whitacre v. Department of Public Health</i>, was brought by Gay and Lesbian Advocates and Defenders (GLAD), a gay-rights organization, on behalf of eight couples from six states. These couples hoped to marry in Massachusetts after the Supreme Judicial Court held in <i>Goodridge v. Department of Public Health</i> that gay couples had the constitutional right to marry under state law.

Decisions of Interest Image

Decisions of Interest

ALM Staff & Law Journal Newsletters

Recent rulings of interest to you and your practice.

Law Guardian or Guardian Ad Litem? Image

Law Guardian or Guardian Ad Litem?

Joel R. Brandes & Bari Brandes Corbin

A law guardian is an attorney who is appointed to ensure that the best interests of the child, who is the subject of the litigation, are served, while the guardian <i>ad litem</i> is a person appointed to protect the rights and interests of a party to the action, who is under a disability. For many years, the appointment of a law guardian has been mandatory in certain Family Court proceedings, such as juvenile delinquency, PINS (Persons in Need of Supervision) and child protective proceedings. See FCA 249(a). Every once in a while we read a decision in which the Supreme Court has appointed a guardian ad litem for a child in a custody case. Such appointments are unusual, since the rights and obligations of the guardian <i>ad litem</i> differ from those of a law guardian. What are the differences, and when is appointment of one or the other appropriate?

An Alternative: Making Drugs Affordable Image

An Alternative: Making Drugs Affordable

ALM Staff & Law Journal Newsletters

The Pharmaceutical Research and Manufacturers of America reported on Feb. 22 that a record number of patients received free or discounted medications from America's pharmaceutical companies last year as part of an industry initiative to help low-income consumers access the medications they need. "PhRMA member companies know a medication that sits on a shelf, out of financial reach of patients, helps no one," said Billy Tauzin, president and chief executive officer of PhRMA. Under these programs, consumers received more than 22 million prescriptions with a wholesale value of $4.17 billion in 2004, up from 18 million prescriptions with a value of $3.4 billion in 2003.

Pharmaceutcial: Why They're So Important in the Med Mal Arena Image

Pharmaceutcial: Why They're So Important in the Med Mal Arena

Janice G. Inman

In this Special Issue, we explore some of the new safeguards that are being proposed and put into place to protect consumers from the unintended side effects of using medications and medical devices. We also look at the controversy surrounding the importation of lower-cost medications from foreign sources, and at one case that highlighted the interplay between medical providers and drug manufacturers in marketing pharmaceutical products.

Features

Should We All Move to Canada? Image

Should We All Move to Canada?

ALM Staff & Law Journal Newsletters

The high cost of prescription medications in the United States has been troubling health care providers and their patients for years. Physicians worry that it will do no good to prescribe a medication to someone who won't be able to afford to buy it, and patients who try to save money by taking less than the prescribed dose worry that that they're putting their health in danger. Any failed medical treatment that harms a patient is fertile ground for a lawsuit against the physician, even if he or she is not the one to blame. Should medical practitioners suggest imported drugs to their patients who might otherwise not be able to afford their prescribed medications?

Features

The TAP Pharmaceutical Acquittals Image

The TAP Pharmaceutical Acquittals

Robert W. Tarun

In 2001, the U.S. Attorney in Boston charged TAP Pharmaceutical Products Inc. (TAP) with conspiring to provide urologists with thousands of free samples of Lupron', for which the doctors billed Medicare and their patients. In order to survive and continue selling its blockbuster product for advanced prostate cancer, TAP made a reasoned decision to pay the government $885 million to resolve both civil and criminal charges. With this resolution, Boston's talented federal prosecutors continued their remarkable success in bringing major pharmaceuticals to their knees and reaching landmark settlements.

Dilemma over Drug Safety Image

Dilemma over Drug Safety

Janice G. Inman

There is a newly urgent push from outside the pharmaceutical research and development community to get drug firms and the government to disclose the results of all tests conducted on new drugs and to immediately reveal information about problems that develop after those drugs go on the market. Consumers and health care providers say they're tired of finding out belatedly that negative information has come to light about the drugs they take or prescribe.

The Impact of Obesity Image

The Impact of Obesity

Michael Brophy

Medical malpractice cases often reflect a series of events unique to one patient, independent of broader health care issues or a larger patient population. On occasion, however, the medico-legal issues of a single case may reflect an overarching social phenomenon, requiring counsel and the courts to address both factors if a just result is to be achieved. This is the story of one such case.

Clinical Trial Injuries Image

Clinical Trial Injuries

Norman M. Goldfarb

The plaintiff's bar has discovered an opportunity in clinical research. The deep pockets of pharmaceutical companies provide one attraction, but attorneys are seldom shy about suing anyone who might even remotely be found liable for an injury. Successful litigation is rare, but the judgments can be expensive. Because of this, many physicians who conduct clinical research are reviewing their medical malpractice insurance policies. Many others, however, have no concept of the looming risks and of whether they are protected by their medical malpractice insurance policies when taking part in clinical trials.

Need Help?

  1. Prefer an IP authenticated environment? Request a transition or call 800-756-8993.
  2. Need other assistance? email Customer Service or call 1-877-256-2472.

MOST POPULAR STORIES

  • Coverage Issues Stemming from Dry Cleaner Contamination Suits
    In recent years, there has been a growing number of dry cleaners claiming to be "organic," "green," or "eco-friendly." While that may be true with respect to some, many dry cleaners continue to use a cleaning method involving the use of a solvent called perchloroethylene, commonly known as perc. And, there seems to be an increasing number of lawsuits stemming from environmental problems associated with historic dry cleaning operations utilizing this chemical.
    Read More ›
  • Bankruptcy Sales: Finding a Diamond In the Rough
    There is no efficient market for the sale of bankruptcy assets. Inefficient markets yield a transactional drag, potentially dampening the ability of debtors and trustees to maximize value for creditors. This article identifies ways in which investors may more easily discover bankruptcy asset sales.
    Read More ›
  • The Flight to Quality and Workplace Experience
    That the pace of change is "accelerating" is surely an understatement. What seemed almost a near certainty a year ago — that law firms would fully and permanently embrace work-from-home — is experiencing a seeming reversal. While many firms have, in fact, embraced hybrid operations, the meaning of hybrid has evolved from "office optional," to an average required 2 days a week, to now many firms coming out with four-day work week mandates — this time, with teeth.
    Read More ›
  • AI or Not To AI: Observations from Legalweek NY 2023
    This year at Legalweek, there was little doubt on what the annual takeaway topic would be. As much as I tried to avoid it for fear of beating the proverbial dead horse, it was impossible not to talk about generative AI, ChatGPT, and all that goes with it. Some fascinating discussions were had and many aspects of AI were uncovered.
    Read More ›